Pure Global
NCT06220162

VAC Regimen for AML Patients Who Failed to Response to VA Regimen

A Clinical Study of Chidamide in Combination With Venetoclax and Azacitidine (VAC) for Patients With Acute Myeloid Leukemia Who Did Not Achieve CR/CRi/MLFS (PR or NR) With One Cycle of Venetoclax and Azacitidine (VA).
The First Affiliated Hospital of Soochow University·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Myeloid Leukemia
Drug/Device/Intervention
chidamide in combination with venetoclax and azacitidine (VAC)
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
The First Affiliated Hospital of Soochow University
Location
Suzhou, China
Timeline & enrollment
Phase
Phase 2
Start date
Feb 01, 2024
End date
Dec 01, 2026
Enrollment
32 participants
Primary outcome

ORR(overall response rate)

Summary

Chidamide in combination with venetoclax and azacitidine (VAC) were expected to improve
 remission rate of patients following to VA regimen treatment failure.

ICD-10 classifications
Myeloid leukaemiaAcute myeloblastic leukaemia [AML]Myeloid leukaemia, unspecifiedAcute myelomonocytic leukaemiaAcute myeloid leukaemia with 11q23-abnormality
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06220162
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06220162 through Pure Global AI's free database. This Phase 2 trial is sponsored by The First Affiliated Hospital of Soochow University and is currently Recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 32 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.